INNO-GENE S.A. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.76 PLN | 0.00% |
|
-1.68% | -20.00% |
| Feb. 14 | Inno-Gene S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Feb. 14 | Inno-Gene S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Inno-Gene SA is a Poland-based holding company engaged in management of a portfolio of companies active in life-science sector through the technology, research and development. Inno-Gene SA's portfolio comprises of Centrum Badan DNA Sp. z o.o., a company that provides services in the field of genetic medical diagnostics, including microbiological diagnosis of infection and the suitability of human congenital diseases using tests performed on DNA microarray technology. On March 22, 2013, the Company established a new subsidiary, Centrum Edukacji Bio-Medycznej Sp. z o.o. On April 11, 2013, the Company established two new indirect subsidiaries, Genomix Sp. z o.o. and Madgenetix Sp. z o.o. In addition, it operates through VitainSillica Sp z o o.
| 1st Jan change | Capi. | |
|---|---|---|
| -20.00% | 2.79M | |
| -4.81% | 3.15B | |
| +31.37% | 2.99B | |
| -14.73% | 2.15B | |
| -14.39% | 1.8B | |
| +70.99% | 1.49B | |
| +23.17% | 770M | |
| -2.18% | 762M | |
| -20.41% | 575M | |
| +3.18% | 308M |
- Stock Market
- Equities
- IGN Stock
- News Inno-Gene S.A.
- Ignitis Expects Debt Repayment, Compensation as Lithuania Enacts Anti-Inflation Measures
